Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Samsung Launches Galaxy Z TriFold to Elevate Its Position in the Foldable Smartphone Market 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
